Safety and Tolerability of Antibody-Drug Conjugates in Cancer

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2019 Jan 17

PMID 30649747

Citations 48

Authors

Anna Wolska-Washer

Tadeusz Robak

Affiliations

Soon will be listed here.

Abstract

Antibody-drug conjugates are monoclonal antibodies attached to biologically active drugs through chemical linkers that deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. Currently, there are about 110 ongoing studies implementing antibody-drug conjugates in the treatment of multiple human malignancies. Antibody-drug conjugates carry a feature of the specificity of a monoclonal antibody and the anti-neoplastic potential of a cytotoxin. The first antibody-drug conjugate was approved in 2001, and the field of antibody-drug conjugates has expanded since then with three more antibody-drug conjugates being added to the market. The complex structure of the antibody-drug conjugate poses a challenge in designing a clinically adequate molecule. Antibody-drug conjugates are usually well tolerated with some predictable adverse reactions, as well as new medical issues, that need careful approach. This review provides an outline of the current status of the efficacy and safety of antibody-drug conjugates in malignant diseases.

Citing Articles

Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis.

Fang W, Ma X, Liu B Hum Vaccin Immunother. 2025; 21(1):2472493.

PMID: 40013384 PMC: 11869778. DOI: 10.1080/21645515.2025.2472493.

Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report.

Rashid A, Kuruvilla P Can J Hosp Pharm. 2025; 78(1):e3614.

PMID: 39816201 PMC: 11722329. DOI: 10.4212/cjhp.3614.

Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer.

Zhu J, Jiang R, Zhang H, Fang Z, Zhou H, Wei Q Discov Oncol. 2024; 15(1):843.

PMID: 39729236 PMC: 11680531. DOI: 10.1007/s12672-024-01705-7.

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.

Dacoregio M, Michelon I, Ernesto do Rego Castro C, de Moraes F, Rossato de Almeida G, Ravani L Breast. 2024; 79:103853.

PMID: 39616817 PMC: 11648803. DOI: 10.1016/j.breast.2024.103853.

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Yang Q, Liu Y RSC Med Chem. 2024; 16(1):50-62.

PMID: 39568595 PMC: 11575643. DOI: 10.1039/d4md00637b.

References

Sievers E, Larson R, Stadtmauer E, Estey E, Lowenberg B, Dombret H . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001; 19(13):3244-54. DOI: 10.1200/JCO.2001.19.13.3244. View

Dowell J, Korth-Bradley J, Liu H, King S, Berger M . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001; 41(11):1206-14. DOI: 10.1177/00912700122012751. View

Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L . Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA.... Br J Haematol. 2010; 149(3):376-82. PMC: 2864316. DOI: 10.1111/j.1365-2141.2010.08095.x. View

Naumovski L, Junutula J . Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010; 12(2):248-57. View

Krop I, Beeram M, Modi S, Jones S, Holden S, Yu W . Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28(16):2698-704. DOI: 10.1200/JCO.2009.26.2071. View

Younes A, Bartlett N, Leonard J, Kennedy D, Lynch C, Sievers E . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-21. DOI: 10.1056/NEJMoa1002965. View

Ricart A . Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17(20):6417-27. DOI: 10.1158/1078-0432.CCR-11-0486. View

Younes A, Gopal A, Smith S, Ansell S, Rosenblatt J, Savage K . Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18):2183-9. PMC: 3646316. DOI: 10.1200/JCO.2011.38.0410. View

Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379(9825):1508-16. DOI: 10.1016/S0140-6736(12)60485-1. View

10.

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30(18):2190-6. DOI: 10.1200/JCO.2011.38.0402. View

11.

Krop I, LoRusso P, Miller K, Modi S, Yardley D, Rodriguez G . A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012; 30(26):3234-41. DOI: 10.1200/JCO.2011.40.5902. View

12.

Davis J, Rock D, Wienkers L, Pearson J . In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos. 2012; 40(10):1927-34. DOI: 10.1124/dmd.112.046169. View

13.

Younes A, Kim S, Romaguera J, Copeland A, Farial S, Kwak L . Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012; 30(22):2776-82. PMC: 5950497. DOI: 10.1200/JCO.2011.39.4403. View

14.

Senter P, Sievers E . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631-7. DOI: 10.1038/nbt.2289. View

15.

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

16.

Hurvitz S, Dirix L, Kocsis J, Bianchi G, Lu J, Vinholes J . Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013; 31(9):1157-63. DOI: 10.1200/JCO.2012.44.9694. View

17.

Petersdorf S, Kopecky K, Slovak M, Willman C, Nevill T, Brandwein J . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-60. PMC: 3682338. DOI: 10.1182/blood-2013-01-466706. View

18.

Gorovits B, Alley S, Bilic S, Booth B, Kaur S, Oldfield P . Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013; 5(9):997-1006. DOI: 10.4155/bio.13.38. View

19.

Han T, Gopal A, Ramchandren R, Goy A, Chen R, Matous J . CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013; 53(8):866-77. PMC: 3777854. DOI: 10.1002/jcph.116. View

20.

Cianfriglia M . The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Ann Ist Super Sanita. 2013; 49(2):150-68. DOI: 10.4415/ANN_13_02_07. View